AI Article Synopsis
- Pharmaceutical opioids are a major concern in India, accounting for 65% of people who inject drugs (PWID), with buprenorphine, pentazocine, and dextropropoxyphene being the most commonly injected.
- The study involved a cross-sectional analysis of 902 male PWIDs from 22 regions, using structured interviews to gather data on drug use patterns and injection practices.
- Findings indicate that pharmaceutical opioid injectors face higher risks of harmful behaviors, such as frequent injection and needle sharing, compared to heroin users, highlighting the need for targeted interventions.
Article Abstract
Introduction And Aims: Injecting pharmaceutical opioids for non-medical purposes is a major concern globally. Though pharmaceutical opioids injection is reported in India, the exact proportion of people who inject drugs (PWID) using pharmaceutical opioids is unknown. The objectives of this study were to describe the various types of drugs that are injected by people in India and to analyse the differences between the commonly injected drugs.
Design And Methods: A cross-sectional, multicentric study covering 22 harm-reduction sites from different regions of the country was conducted. First 50 subjects, chosen randomly from a list of PWIDs accessing services from each site and fulfilling study criteria, were interviewed using a structured questionnaire. Data from 902 male subjects are presented here.
Results: Pharmaceutical opioid injectors (POI) accounted for 65% of PWIDs (buprenorphine: 30.8%, pentazocine: 21.8% and dextropropoxyphene: 11.9%). Heroin, injected by 34.3%, was prevalent in most states surveyed. Buprenorphine and pentazocine were not injected in the north-east region, whereas dextropropoxyphene was injected in the north-east alone. Univariate and multivariate logistic regression showed that, compared with heroin injectors, the POI group was more likely to consume alcohol and pharmaceutical opioids orally, inject frequently, share needle/syringes and develop injection-site complications. Among individual POIs, buprenorphine injectors had significantly higher proportion of subjects injecting frequently, sharing needle/syringes and developing local complications. Irrespective of the opioid type, majority of subjects were opioid dependent.
Discussion And Conclusions: Pharmaceutical opioids are the most common drugs injected in India currently and have greater injection-related risks and complications. Significant differences exist between different pharmaceutical opioids, which would be important considerations for interventions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dar.12208 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine.
Clin Drug Investig
January 2025
Cali Biosciences, US, LLC, San Diego, CA, USA.
Background And Objective: There is a significant medical need for improved long-acting local anesthetics to decrease postsurgical pain and reduce postoperative opioid use. While ropivacaine is considered a safer local anesthetic than bupivacaine, no long-acting ropivacaine formulation is currently marketed. Available formulations of bupivacaine show inconsistent pharmacokinetics (PK) among different surgical models, and inconsistency in PK may lead to a reluctance to use the medication owing to fear of local anesthetic systemic toxicity (LAST) or unreliable efficacy.
View Article and Find Full Text PDFSynthesis and biological evaluation of new dual APN/NEP inhibitors as potent analgesics.
Bioorg Chem
January 2025
School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. Electronic address:
An alternative approach for the management of acute and chronic pains involves prolonging the half-life of endogenous opiates, such as enkephalins that are released in response to nociceptive stimuli. This can be achieved through the inhibition of enzymatic pathways responsible for the hydrolysis of these peptides, particularly targeting Aminopeptidase N (APN) and Neutral Endopeptidase (NEP). In this study, we designed and synthesized a series of dual enkephalinase inhibitors (DENKIs) targeting both APN and NEP as novel analgesic treatments.
View Article and Find Full Text PDFIn vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.
Clin Transl Sci
February 2025
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Tramadol, the 41st most prescribed drug in the United States in 2021 is a prodrug activated by CYP2D6, which is highly polymorphic. Previous studies showed enzyme-inhibitor affinity varied between different CYP2D6 allelic variants with dextromethorphan and atomoxetine metabolism. However, no study has compared tramadol metabolism in different CYP2D6 alleles with different CYP2D6 inhibitors.
View Article and Find Full Text PDFFinding new ways to treat overdoses.
Elife
January 2025
Department of Pharmaceutical Sciences, University of Kentucky, Lexington, United States.
Reversing opioid overdoses in rats using a drug that does not enter the brain prevents the sudden and severe withdrawal symptoms associated with therapeutics that target the central nervous system.
View Article and Find Full Text PDFAdvanced Pain Management in Patients with Terminal Cancer.
Curr Med Chem
January 2025
Department of Surgery, School of Medicine, Nazarbayev University, 5/1 Kerey and Zhanibek khandar str., 020000, Astana, Kazakhstan.
Understanding and managing pain in patients with terminal cancer is a vital aspect of palliative care, aimed at relieving suffering and improving quality of life in the final stages of illness. Studies indicate that approximately 50% of patients with stage 4 cancer report moderate to severe pain, with a quarter experiencing severe cancer-related pain. Despite opioid prescriptions in 97% of cases, a significant portion of patients continues to suffer unresolved pain during the last week of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!